Review



foxa1  (Obio Technology Corp Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Obio Technology Corp Ltd foxa1
    Foxa1, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxa1/product/Obio Technology Corp Ltd
    Average 86 stars, based on 1 article reviews
    foxa1 - by Bioz Stars, 2026-05
    86/100 stars

    Images



    Similar Products

    foxa1 / hnf3a (foxa1/1514)  (Biotium)
    93
    Biotium foxa1 / hnf3a (foxa1/1514)
    Foxa1 / Hnf3a (Foxa1/1514), supplied by Biotium, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxa1 / hnf3a (foxa1/1514)/product/Biotium
    Average 93 stars, based on 1 article reviews
    foxa1 / hnf3a (foxa1/1514) - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    gene exp foxa1 hs04187555 m1  (Thermo Fisher)
    97
    Thermo Fisher gene exp foxa1 hs04187555 m1
    Gene Exp Foxa1 Hs04187555 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gene exp foxa1 hs04187555 m1/product/Thermo Fisher
    Average 97 stars, based on 1 article reviews
    gene exp foxa1 hs04187555 m1 - by Bioz Stars, 2026-05
    97/100 stars
    		  Buy from Supplier
    guinea pig anti foxa1  (Proteintech)
    96
    Proteintech guinea pig anti foxa1
    Guinea Pig Anti Foxa1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/guinea pig anti foxa1/product/Proteintech
    Average 96 stars, based on 1 article reviews
    guinea pig anti foxa1 - by Bioz Stars, 2026-05
    96/100 stars
    		  Buy from Supplier
    sonication  (Proteintech)
    93
    Proteintech sonication
    Sonication, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sonication/product/Proteintech
    Average 93 stars, based on 1 article reviews
    sonication - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    foxa1  (Obio Technology Corp Ltd)
    86
    Obio Technology Corp Ltd foxa1
    Foxa1, supplied by Obio Technology Corp Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/foxa1/product/Obio Technology Corp Ltd
    Average 86 stars, based on 1 article reviews
    foxa1 - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier
    anti foxa1 antibody  (Proteintech)
    93
    Proteintech anti foxa1 antibody
    Anti Foxa1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti foxa1 antibody/product/Proteintech
    Average 93 stars, based on 1 article reviews
    anti foxa1 antibody - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    antibodies for foxa1  (Santa Cruz Biotechnology)
    93
    Santa Cruz Biotechnology antibodies for foxa1
    Verification of mRNA and protein level expression in <t>FOXA1</t> siRNA-treated ovarian cancer cells. ( a ) FOXA1 mRNA expression after FOXA1 siRNA transfection. ( b ) Quantification of FOXA1 protein expression. ( c ) Representative Western blot images of FOXA1 and β-actin after FOXA1 siRNA transfection.
    Antibodies For Foxa1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/antibodies for foxa1/product/Santa Cruz Biotechnology
    Average 93 stars, based on 1 article reviews
    antibodies for foxa1 - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    human foxa1 small interfering rna  (Bioneer Corporation)
    86
    Bioneer Corporation human foxa1 small interfering rna
    Verification of mRNA and protein level expression in <t>FOXA1</t> siRNA-treated ovarian cancer cells. ( a ) FOXA1 mRNA expression after FOXA1 siRNA transfection. ( b ) Quantification of FOXA1 protein expression. ( c ) Representative Western blot images of FOXA1 and β-actin after FOXA1 siRNA transfection.
    Human Foxa1 Small Interfering Rna, supplied by Bioneer Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human foxa1 small interfering rna/product/Bioneer Corporation
    Average 86 stars, based on 1 article reviews
    human foxa1 small interfering rna - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    Verification of mRNA and protein level expression in FOXA1 siRNA-treated ovarian cancer cells. ( a ) FOXA1 mRNA expression after FOXA1 siRNA transfection. ( b ) Quantification of FOXA1 protein expression. ( c ) Representative Western blot images of FOXA1 and β-actin after FOXA1 siRNA transfection.

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Verification of mRNA and protein level expression in FOXA1 siRNA-treated ovarian cancer cells. ( a ) FOXA1 mRNA expression after FOXA1 siRNA transfection. ( b ) Quantification of FOXA1 protein expression. ( c ) Representative Western blot images of FOXA1 and β-actin after FOXA1 siRNA transfection.

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Expressing, Transfection, Western Blot

    Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and HEYA8 ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Cell proliferation analysis to silence of FOXA1 in ovarian cancer cells. FOXA1 silencing in SK-OV3 and HEYA8 ovarian cancer cell lines reduces cell proliferation compared to control. (* p < 0.01).

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Control

    Cell migration, invasion, and wound healing assay to silence of FOXA1 in ovarian cancer cells. ( a ) FOXA1 si decreased the migration ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( b ) FOXA1 si decreased the invasion ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( c ) Representative images of the wound healing assay at 0, 12, 24, 36, and 48 h time points (Left: SK-OV3, Right: HEYA8). ( d ) The quantitative evaluation and statistical analysis of wound area percentage in wound healing assay measured by Image J software. Results are expressed as mean ± SD of five experiments (Left: SK-OV3, Right: HEYA8).

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Cell migration, invasion, and wound healing assay to silence of FOXA1 in ovarian cancer cells. ( a ) FOXA1 si decreased the migration ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( b ) FOXA1 si decreased the invasion ability of ovarian cancer cells (Left: SK-OV3, Right: HEYA8). ( c ) Representative images of the wound healing assay at 0, 12, 24, 36, and 48 h time points (Left: SK-OV3, Right: HEYA8). ( d ) The quantitative evaluation and statistical analysis of wound area percentage in wound healing assay measured by Image J software. Results are expressed as mean ± SD of five experiments (Left: SK-OV3, Right: HEYA8).

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Migration, Wound Healing Assay, Software

    Comparison of EMT gene expression after treatment with FOXA1 siRNA. ( a ) Changes in EMT gene expression in HEYA8. ( b ) Changes in EMT gene expression in SK-OV3. ( c ) Schematic representation of EMT and MET processes and their key molecular markers.

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Comparison of EMT gene expression after treatment with FOXA1 siRNA. ( a ) Changes in EMT gene expression in HEYA8. ( b ) Changes in EMT gene expression in SK-OV3. ( c ) Schematic representation of EMT and MET processes and their key molecular markers.

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Comparison, Gene Expression

    Reduction in chemoresistance following FOXA1 Gene Knockdown. ( a ) Determining IC50 values using carboplatin. ( b ) Atezolizumab cytotoxicity test in SK-OV3 and HEY A8 cells. ( c , d ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without atezolizumab. ( e , f ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without FOXA1 knockdown. ( g , h ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following combined treatment with carboplatin and atezolizumab, with or without FOXA1 knockdown. ( i , j ) Comparison of cell viability in FOXA1-silenced SK-OV3 and HEYA8 cells treated with carboplatin alone or in combination with atezolizumab.

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Reduction in chemoresistance following FOXA1 Gene Knockdown. ( a ) Determining IC50 values using carboplatin. ( b ) Atezolizumab cytotoxicity test in SK-OV3 and HEY A8 cells. ( c , d ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without atezolizumab. ( e , f ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following carboplatin treatment with or without FOXA1 knockdown. ( g , h ) Cell viability of SK-OV3 and HEYA8 ovarian cancer cells following combined treatment with carboplatin and atezolizumab, with or without FOXA1 knockdown. ( i , j ) Comparison of cell viability in FOXA1-silenced SK-OV3 and HEYA8 cells treated with carboplatin alone or in combination with atezolizumab.

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Knockdown, Comparison

    Immunohistochemical analysis of FOXA1 expression in ovarian cancer patient tissue samples. ( a ) High expression of FOXA1. ( b ) Low expression of FOXA1. ( c ) Malignant tumor patients stratified by stage (I–IV) ( p < 0.05). ( d ) Patients under fifty years old stratified into normal, benign, and tumor groups ( p < 0.05). ( e ) Patients under fifty years old stratified by benign vs. tumor only ( p < 0.05).

    Journal: International Journal of Molecular Sciences

    Article Title: FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy

    doi: 10.3390/ijms27031194

    Figure Lengend Snippet: Immunohistochemical analysis of FOXA1 expression in ovarian cancer patient tissue samples. ( a ) High expression of FOXA1. ( b ) Low expression of FOXA1. ( c ) Malignant tumor patients stratified by stage (I–IV) ( p < 0.05). ( d ) Patients under fifty years old stratified into normal, benign, and tumor groups ( p < 0.05). ( e ) Patients under fifty years old stratified by benign vs. tumor only ( p < 0.05).

    Article Snippet: The membranes were incubated overnight at 4 °C with primary antibodies for FOXA1 (Santa Cruz, Dallas, TX, USA, sc-101058, 1:1000) and β-actin (Santa Cruz, Dallas, TX, USA, sc-47778, 1:1000).

    Techniques: Immunohistochemical staining, Expressing